- Relapsing forms of MS (RMS):
- Clinically isolated syndrome
- Relapsing-remitting MS (RRMS)
- Active secondary progressive MS (SPMS)
Dose:300 mg IV → followed 2 weeks later by another 300 mg IV
- Primary Progressive MS (PPMS)
Dose:600 mg IV every 6 months (starting 6 months after initial dose)
- 300 mg/10 mL (30 mg/mL) in a single-dose vial
- Must be diluted before IV infusion
- Administer by IV infusion only
- Premedicate 30–60 minutes before infusion with:
- Methylprednisolone (or equivalent corticosteroid)
- Antihistamine (e.g., diphenhydramine)
- Optional antipyretic (e.g., acetaminophen)
- Infusion duration:
- Initial doses over 2.5–3.5 hours
- May reduce time in future if tolerated
- Mechanism of Action:
- Humanized monoclonal antibody targeting CD20+ B cells
- Reduces inflammation and immune-mediated CNS damage in MS
- Pharmacokinetics:
- Half-life: ~26 days
- Cleared via reticuloendothelial system
- Infusion reactions (rash, fever, hypotension)
- Respiratory tract infections
- Skin infections
- Headache, fatigue
- Active hepatitis B infection
- History of life-threatening reaction to Ocrelizumab
- Avoid live or live-attenuated vaccines
- Caution with other immunosuppressants (risk of infection ↑)
- Monitor closely when used with other monoclonal antibodies
Drug Status
Availability | |
Pregnancy | |
Breastfeeding | |
Schedule |
BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
---|---|---|---|---|---|
Ocrevus | 300mg/10mL | Injection | 1’s | F.Hoffman La-Roche | Roche Kenya |